EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum

Suchada Kaewin, Cecilia Leijding, Stefano Gastaldello, David Makari, Yi Zhong, Kristofer M Andreasson, Kent Jardemark, Maryam Dastmalchi, Begum Horuluoglu, Helene Alexanderson, Volker M Lauschke, Ingrid E Lundberg und 1 weitere

Annals of the Rheumatic Diseases · 2026-06 · 85 (6) · 1180-1190

DOI: 10.1016/j.ard.2026.02.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Suchada Kaewin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Dermatomyositis, Receptor, Interferon alpha-beta, Muscle Weakness. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation King Gustaf V 80-årsfond, Swedish Cancer Society, Swedish Rheumatism Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Dermatomyositis (DM) is characterised by systemic inflammation, debilitating muscle weakness, cutaneous lesions, and increased mortality. An upregulation of type I interferon (IFN)-stimulated genes is observed in patients with DM. However, it remains unclear whether type I IFNs cause muscle weakness in DM. This study aimed to investigate the role of IFN-α/β receptor signalling in muscle weakness induced by factors in DM serum. METHODS: In ex vivo experiments, flexor digitorum brevis muscles were isolated from healthy mice and incubated 24 hours with 10% healthy serum or serum from patients with DM (n = 9). To modulate IFN signalling, an antibody against the type I IFN receptor α/β subunit 1 (IFNAR1) or the Janus kinase-signal transducer and activator of transcription inhibitor ruxolitinib was used. RNA sequencing, followed by bioinformatics analysis, was conducted to identify differentially expressed genes and affected pathways related to IFN signalling. RESULTS: Incubation with serum from patients with DM, but not that from healthy controls, caused significant muscle weakness manifested by a reduction in muscle force. Bioinformatic analyses revealed downregulation of type I IFN-inducible genes with IFNAR1 antibody. Pathway analysis showed enrichment of several IFN-related pathways. Inhibition of type I IFN signalling with either an IFNAR1 antibody or ruxolitinib abolished DM serum-induced effects. CONCLUSIONS: Factors in serum from patients with DM can activate the type I IFN signalling pathway in skeletal muscles, which constitutes an important causal factor for muscle weakness. Our data support a mechanistic model where blood-borne factors contribute to muscle disease phenotypes and underscore the therapeutic possibilities of pharmacological interventions targeting the IFNAR1 signalling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisReceptor, Interferon alpha-betaMuscle WeaknessAnimalsHumansSignal TransductionPyrimidinesNitrilesMiceMalePyrazolesFemaleMuscle, SkeletalInterferon Type I

Substanzen

Receptor, Interferon alpha-betaPyrimidinesNitrilesruxolitinibPyrazolesInterferon Type I

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Pharmaceutical Informatics Institute, College of Pha…
  • Department of Medicine, Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Women's Health and Allied Health Professionals Theme, Medical Unit Allied Health Profess…
  • Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden; Department of Gastro, Dermatology and…
  • Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Dr Margarete Fischer-Bosch Institute of Clinical Pha…

Förderung

  • Foundation King Gustaf V 80-årsfond
  • Swedish Cancer Society
  • Swedish Rheumatism Association
  • Promobilia foundation
  • Robert Bosch Foundation
  • Heart and Lung Foundation
  • Foundation King Gustaf V Jubilee Fund
  • Swedish Research Council

Zitieren

APA

Kaewin, S., Leijding, C., Gastaldello, S., Makari, D., Zhong, Y., Andreasson, K. M., Jardemark, K., Dastmalchi, M., Horuluoglu, B., Alexanderson, H., Lauschke, V. M., Lundberg, I. E., & Andersson, D. C. (2026). Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum. Annals of the Rheumatic Diseases, 85(6), 1180-1190. https://doi.org/10.1016/j.ard.2026.02.018

Vancouver

Kaewin S, Leijding C, Gastaldello S, Makari D, Zhong Y, Andreasson KM, et al. Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum. Annals of the Rheumatic Diseases. 2026;85(6):1180-1190. doi:10.1016/j.ard.2026.02.018

BibTeX
@article{Kaewin2026,
  author = {Kaewin, Suchada and Leijding, Cecilia and Gastaldello, Stefano and Makari, David and Zhong, Yi and Andreasson, Kristofer M and Jardemark, Kent and Dastmalchi, Maryam and Horuluoglu, Begum and Alexanderson, Helene and Lauschke, Volker M and Lundberg, Ingrid E and Andersson, Daniel C},
  title = {Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {6},
  pages = {1180--1190},
  doi = {10.1016/j.ard.2026.02.018}
}
Kostenlos starten →